We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

068270:KRXCelltrion, Inc. Analysis

Data as of 2026-03-10 - not real-time

₩206,000.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Celltrion is trading at 206,000 KRW, comfortably above the 30‑day support of 195,900 KRW but still below the 20‑day (228,520 KRW) and 50‑day (214,522 KRW) moving averages. The RSI of 41 signals a modestly oversold condition, while the bearish MACD histogram and a negative MACD line versus a positive signal line point to short‑term downward momentum. Volume trends are decreasing and 30‑day volatility is high at nearly 59 %, suggesting a choppy price environment. On the fundamentals side, revenue grew 16.7 % year‑over‑year and margins remain robust (gross 55 %, operating 29 %). However, the company carries an elevated debt‑to‑equity ratio of over 17, making its balance sheet a notable risk factor despite strong operating cash flow. The forward P/E of 29.7 sits above the industry average of 25.2, indicating the stock may be priced at a premium relative to peers.
Analysts are optimistic, with a consensus “buy” and a median target of 260,000 KRW, implying roughly 23 % upside from the current level. The Fear & Greed Index at 76.75 classifies market sentiment as “Extreme Greed,” which could inflate short‑term expectations. Dividend yield is modest at 0.37 % and the payout ratio under 20 % appears sustainable given positive free cash flow. The low beta of 0.5 suggests limited correlation with broader market swings, tempering systematic risk. Given the mix of strong growth drivers, high leverage, and mixed technical signals, the stock sits in a “fair” valuation zone with a “blend” growth‑value profile. Investors should weigh the upside potential against the near‑term bearish momentum and the company’s debt load when timing entry or exit points.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price near support level
  • bearish MACD and decreasing volume
  • high short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • 16.7% revenue growth
  • analyst target indicating ~23% upside
  • solid operating margins

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • diverse global pipeline of biosimilars
  • sustainable dividend with low payout ratio
  • low beta reducing market risk

Key Metrics & Analysis

Financial Health

Revenue Growth16.70%
Profit Margin18.94%
P/E Ratio29.7
ROE4.36%
ROA2.69%
Debt/Equity17.17
Op. Cash Flow₩812.1B
Free Cash Flow₩393.4B
Industry P/E25.2

Technical Analysis

TrendBullish
RSI41.0
Support₩195,900.00
Resistance₩251,000.00
MA 20₩228,520.00
MA 50₩214,522.00
MA 200₩182,989.52
MACDBearish
VolumeDecreasing
Fear & Greed Index76.75

Valuation

Fair Value₩41,144.56
Target Price₩253,695.66
Upside/Downside23.15%
GradeFair
TypeBlend
Dividend Yield0.37%

Risk Assessment

Beta0.50
Volatility58.86%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.